DealBook (Free subscription) | 30/09/2008
ImClone Systems, the biotechnology company controlled by Carl C. Icahn, said a drug maker that proposed a $6.1 billion takeover would make a formal bid or withdraw by the end of the day on Wednesday. Mr. Icahn, ImClone’s chairman and second-biggest shareholder, disclosed on Sept. 10 the offer of $70 a share from a “large pharmaceutical [...]
DealBook (Free subscription) | 5 hours ago
... 17 percent of ImClone, had originally bid $60 a share for the rest of ImClone it did not own. But Carl C. Icahn, the billionaire who controls ImClone and is its chairman, rejected that offer as too low and said that a large pharmaceutical company was interested in paying $70 a share.ImClone has said the bid would not be subject to financing, an important consideration given the tightness...
PR News Wire (Free subscription) | 7 hours ago
... shares in the tender offer. Additionally, certain entities associated with ImClone's chairman, Carl C. Icahn, holding approximately 14 percent of ImClone's outstanding common stock, have agreed to tender their shares in the tender offer. This strategic combination will create one of the leading oncology franchises in the biopharmaceutical industry, offering both targeted therapies...
DealBook (Free subscription) | 01/10/2008
Eli Lilly is in talks with ImClone Systems about buying the maker of the cancer-fighting drug Erbitux for $6.1 billion, a person briefed on the matter said. The talks, which ImClone chairman Carl C. Icahn hinted at earlier this week, would seek to derail a hostile $4.7 billion from Bristol-Myers Squibb for the 83 percent [...]
